The correlation between asthma control and health status: The GOAL study

European Respiratory Journal

Volumn 29, Issue 1, 2007, Pages 59-63

  Bateman, E D ^a,g   Bousquet, J ^b   Keech, M L ^c   Busse, W W ^e   Clark, T J H ^d   Pedersen, S E ^f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c GLAXOSMITHKLINE   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Asthma; Control; Fluticasone propionate; Health status; Quality of life; Salmeterol

Indexed keywords

FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; ANDROSTANE DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; FLUTICASONE; FLUTICASONE PROPIONATE - SALMETEROL COMBINATION; FLUTICASONE PROPIONATE SALMETEROL COMBINATION; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; ADOLESCENT; COMPARATIVE STUDY; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; MIDDLE AGED; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HEALTH STATUS; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33846240851     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00128505     Document Type: Article

References (19)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report (publication No. 02-3659). Bethesda, National Institutes of Health, National Heart, Lung, and Blood Institute, 2002.
2. National Asthma Education Prevention Program. Guidelines for the diagnosis and management of asthma. Expert panel report 2 (publication No. 97-4051). Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute, 1997.
3. Rabe KF, Vermeire PA, Soriano J, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16:802-807.
4. Jones KG, Bell J, Fehrenbach C, Pearce L, Grimley D, McCarthy TP. Understanding patient perceptions of asthma: results of the Asthma Control and Expectations (ACE) survey. Int J Clin Pract 2002; 56: 89-93.
5. Juniper FF. The impact of patient compliance on effective asthma management. Curr Opin Pulm Med 2003; 9: Suppl. 1, S8-S10.
6. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999; 14: 1038-1043.
7. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 2002; 121: 1824-1832.
8. Carranza Rosenzweig JR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 2004; 98: 1157-1165.
9. Ederle K, on behalf of the Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: an open-label, randomised study. Eur Rev Med Pharmacol Sci 2003; 7: 45-55.
10. Thoonen BP, Schermer TR, Van Den Boom G, et al. Self management of asthma in general practice, asthma control and quality of life: a randomised controlled trial. Thorax 2003; 58: 30-36.
11. Katz PP, Yelin EH, Eisner MD, Blanc PD. Perceived control of asthma and quality of life among adults with asthma. Ann Allergy Asthma Immunol 2002; 89: 251-258.
12. Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001; 17: 589-595.
13. Bateman ED, Frith LF, Braunstein GL. Achieving guideline-based asthma control: does the patient benefit? Eur Respir J 2002; 20: 588-595.
14. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control, study. Am J Respir Crit Care Med 2004; 170: 836-844.
15. Bateman E, Pauwels R, Boushey H, et al. Aiming for Total Control of asthma significantly improves asthma-related quality of life: salmeterol/ fluticasone propionate versus fluticasone propionate alone. Am J Respir Crit Care Med 2004; 169: A87.
16. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
17. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-87.
18. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19: 398-404.
19. Juniper EF, Bousquet J, Abetz L, Bateman ED, the GOAL Committee. Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616-621.